NDA 010379 · King Pharms
Cytomel
Liothyronine Sodium · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jan 21, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1956
May 8, 1956
Approved uses
1
Original approval plus efficacy supplements
Registered trials
237
35 Phase 3, 24 recruiting
FAERS reports
8,771
3,983 serious, 208 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS • Thyroid hormones, including LIOTHYRONINE SODIUM, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. • In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning. • Thyroid hormones, including liothyronine sodium, should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily...
What it is approved for
From the label in effect Jun 4, 2026.
Liothyronine sodium is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) • Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) • Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 ) Limitations of Use : - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. ( 1 ) - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. ( 1 ) 1.1 Hypothyroidism Liothyronine sodium is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. 1.2 Pituitary Thyroid-Stimulating Hormone (TSH) Suppression Liothyronine sodium is indicated as an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer . 1.3 Thyroid Suppression Test Liothyronine sodium is indicated as a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Limitations of Use • Liothyronine sodium is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with liothyronine sodium may induce hyperthyroidism [see Warnings and Precautions (5.4) ] . • Liothyronine sodium is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
Mechanism: Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 8, 1956 Original approval · Type 1 - New Molecular Entity · priority review
3 products under this application
- CYTOMEL · LIOTHYRONINE SODIUM EQ 0.025MG BASE · TABLET, ORAL · Prescription · TE AB
- CYTOMEL · LIOTHYRONINE SODIUM EQ 0.05MG BASE · TABLET, ORAL · Prescription · TE AB
- CYTOMEL · LIOTHYRONINE SODIUM EQ 0.005MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Liothyronine" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Sequenced Treatment Alternatives to Relieve Depression (STAR*D)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00021528 · 4,000 participants · Start Jul 2001
Drug: citalopram; BuproprionSR and 8 more · For: Depression
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Chula Vista, California · 41 sites in all
- Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)Pivotal-lookingActive, not recruiting
Lisette NixonGovernment (non-federal)
NCT02215265 · 1,269 participants (planned) · Start Oct 2015 · Primary completion Oct 2027
Drug: Cisplatin · For: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Sites: Redwood City, California; Orlando, Florida; Houston, Texas · 57 sites in all
- Radiation Therapy, Surgery, and Chemotherapy in Treating Patients With Rectal Cancer That Can Be Surgically RemovedPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00002523 · 1,011 participants · Start Apr 1993 · Primary completion Mar 2003
Drug: fluorouracil; leucovorin calcium · For: Colorectal Cancer
Sites: Brussels, Belgium; Charleroi, Belgium; La Louvière, Belgium · 35 sites in all
Institut du Cancer de Montpellier - Val d'AurelleAcademic, hospital or other
NCT04025541 · 992 participants (planned) · Start May 29, 2018 · Primary completion May 29, 2029
Drug: Blood sampling; Blood sampling C3 and 7 more · For: Cancer; Breast Cancer; Sarcoma and 3 more
Sites: Montpellier, France · 2 sites in all
- Tocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of GestationPivotal-lookingActive, not recruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT03976063 · 857 participants · Start Oct 7, 2019 · Primary completion Nov 2026
Drug: Nifedipine; Placebo of Nifedipine · For: Preterm Premature Rupture of Membrane
Sites: Paris, France
Institut du Cancer de Montpellier - Val d'AurelleAcademic, hospital or other
NCT07085429 · 750 participants (planned) · Start Nov 25, 2025 · Primary completion Sep 2030
Drug: Blood and tissue sampling · For: Lung Cancer; Bronchial Cancer
Sites: Montpellier, France
- Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTCPivotal-lookingNot yet recruiting
West China HospitalAcademic, hospital or other
NCT07239674 · 646 participants (planned) · Start Nov 30, 2025 · Primary completion Nov 30, 2027
Drug: desiccated thyroid extract (DTE)+levothyroxine (L-T4) · For: Intermediate-to-High Risk Differentiated Thyroid Cancer
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective969
- headache887
- fatigue860
- nausea587
- dyspnoea562
- pain491
- hypertension471
- malaise451
- weight increased443
- hypothyroidism433
- feeling abnormal420
- dizziness402
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 79 |
| 2005 | 91 |
| 2006 | 79 |
| 2007 | 129 |
| 2008 | 170 |
| 2009 | 153 |
| 2010 | 269 |
| 2011 | 229 |
| 2012 | 294 |
| 2013 | 314 |
| 2014 | 314 |
| 2015 | 515 |
| 2016 | 727 |
| 2017 | 472 |
| 2018 | 558 |
| 2019 | 560 |
| 2020 | 640 |
| 2021 | 505 |
| 2022 | 946 |
| 2023 | 510 |
| 2024 | 443 |
| 2025 | 427 |
| 2026 | 347 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cytomel (Liothyronine Sodium)
2024 spending
$414K
Beneficiaries
2,398
8,950 claims
Per beneficiary
$173
$0.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,745,206 |
| 2021 | $2,527,213 |
| 2022 | $1,974,217 |
| 2023 | $2,005,765 |
| 2024 | $414,478 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Treatment Preferences in Patients With Hypothyroidism.
de Lima Beltrão FE, Carvalhal G, de Almeida Beltrão DC, et al. · J Clin Endocrinol Metab 2025 · Meta-Analysis, Network Meta-Analysis
- Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism.
Shakir MKM, Brooks DI, McAninch EA, et al. · J Clin Endocrinol Metab 2021 · Comparative Study, Randomized Controlled Trial
- Hypothyroidism (primary).
Nygaard B · BMJ Clin Evid 2007 · Systematic Review
- Hypothyroidism (primary).
Nygaard B · BMJ Clin Evid 2014 · Systematic Review
- Hypothyroidism (primary).
Nygaard B · BMJ Clin Evid 2010 · Systematic Review
Sponsor: King Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.